Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab vs Platinum-Based Chemotherapy in First-Line PD-L1+ Advanced NSCLC
2024-515052-20-00Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of cemiplimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Overall survival and Progression-free survival by blinded independent review. Started Sep 2024; status: completed.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-515052-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515052-20-00.